124 related articles for article (PubMed ID: 38669077)
1. Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for prognosis and for early detection of relapse in locally advanced cervical cancer.
Sivars L; Jylhä C; Crona Guterstam Y; Zupancic M; Lindqvist B; Nordenskjöld M; Tham E; Hellman K
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38669077
[TBL] [Abstract][Full Text] [Related]
2. Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer.
Sivars L; Hellman K; Crona Guterstam Y; Holzhauser S; Nordenskjöld M; Falconer H; Palsdottir K; Tham E
Gynecol Oncol; 2022 Oct; 167(1):107-114. PubMed ID: 35918201
[TBL] [Abstract][Full Text] [Related]
3. The current status of cell-free human papillomavirus DNA as a biomarker in cervical cancer and other HPV-associated tumors: A review.
Sivars L; Palsdottir K; Crona Guterstam Y; Falconer H; Hellman K; Tham E
Int J Cancer; 2023 Jun; 152(11):2232-2242. PubMed ID: 36274628
[TBL] [Abstract][Full Text] [Related]
4. HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer.
Cabel L; Bonneau C; Bernard-Tessier A; Héquet D; Tran-Perennou C; Bataillon G; Rouzier R; Féron JG; Fourchotte V; Le Brun JF; Benoît C; Rodrigues M; Scher N; Minsat M; Legrier ME; Bièche I; Proudhon C; Sastre-Garau X; Bidard FC; Jeannot E
ESMO Open; 2021 Jun; 6(3):100154. PubMed ID: 34022731
[TBL] [Abstract][Full Text] [Related]
5. [ctHPV-DNA based precision oncology for patients with oropharyngeal cancer - Where are we?].
Wuerdemann N; Joosse S; Klasen C; Prinz J; Demers I; George J; Speel EM; Wagner S; Klußmann JP
Laryngorhinootologie; 2023 Oct; 102(10):728-734. PubMed ID: 37364603
[TBL] [Abstract][Full Text] [Related]
6. Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay.
Galati L; Combes JD; Le Calvez-Kelm F; McKay-Chopin S; Forey N; Ratel M; McKay J; Waterboer T; Schroeder L; Clifford G; Tommasino M; Gheit T
Microbiol Spectr; 2022 Apr; 10(2):e0148021. PubMed ID: 35225653
[TBL] [Abstract][Full Text] [Related]
7. Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer.
Jeannot E; Latouche A; Bonneau C; Calméjane MA; Beaufort C; Ruigrok-Ritstier K; Bataillon G; Larbi Chérif L; Dupain C; Lecerf C; Popovic M; de la Rochefordière A; Lecuru F; Fourchotte V; Jordanova ES; von der Leyen H; Tran-Perennou C; Legrier ME; Dureau S; Raizonville L; Bello Roufai D; Le Tourneau C; Bièche I; Rouzier R; Berns EMJJ; Kamal M; Scholl S
Clin Cancer Res; 2021 Nov; 27(21):5869-5877. PubMed ID: 34210686
[TBL] [Abstract][Full Text] [Related]
8. Practical Application of Circulating Tumor-Related DNA of Human Papillomavirus in Liquid Biopsy to Evaluate the Molecular Response in Patients with Oropharyngeal Cancer.
Mazurek AM; Rutkowski TW
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831390
[TBL] [Abstract][Full Text] [Related]
9. Predicting Response to Radical Chemoradiotherapy with Circulating HPV DNA (cHPV-DNA) in Locally Advanced Uterine Cervix Cancer.
Lalondrelle S; Lee J; Cutts RJ; Garcia Murillas I; Matthews N; Turner N; Harrington K; Vroobel K; Moretti E; Bhide SA
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900180
[TBL] [Abstract][Full Text] [Related]
10. A new marker based on risk stratification of human papillomavirus DNA and tumor size to predict survival of locally advanced cervical cancer.
Huang Y; He Q; Xu K; Zhou J; Yin J; Li F; Feng M; Lang J
Int J Gynecol Cancer; 2019 Mar; 29(3):459-465. PubMed ID: 30733276
[TBL] [Abstract][Full Text] [Related]
11. Digital droplet PCR-based quantification of ccfHPV-DNA as liquid biopsy in HPV-driven cervical and vulvar cancer.
Thangarajah F; Busshoff J; Salamon J; Pruss MS; Lenz C; Morgenstern B; Hellmich M; Schlößer HA; Lenz M; Domröse C; Mallmann MR; Mallmann P; Weiß J; Franzen F; Merkelbach-Bruse S; Binot E; Eich ML; Büttner R; Schultheis AM; Alidousty C
J Cancer Res Clin Oncol; 2023 Nov; 149(14):12597-12604. PubMed ID: 37452202
[TBL] [Abstract][Full Text] [Related]
12. Liquid biopsy of HPV DNA in cervical cancer.
Cheung TH; Yim SF; Yu MY; Worley MJ; Fiascone SJ; Chiu RWK; Lo KWK; Siu NSS; Wong MCS; Yeung ACM; Wong RRY; Chen ZG; Elias KM; Chung TKH; Berkowitz RS; Wong YF; Chan PKS
J Clin Virol; 2019 May; 114():32-36. PubMed ID: 30913520
[TBL] [Abstract][Full Text] [Related]
13. Circulating Human Papillomavirus DNA as a Biomarker of Response in Patients With Locally Advanced Cervical Cancer Treated With Definitive Chemoradiation.
Han K; Leung E; Barbera L; Barnes E; Croke J; Di Grappa MA; Fyles A; Metser U; Milosevic M; Pintilie M; Wolfson R; Zhao Z; Bratman SV
JCO Precis Oncol; 2018 Nov; 2():1-8. PubMed ID: 35135145
[TBL] [Abstract][Full Text] [Related]
14. Liquid Biopsies with Circulating Plasma HPV-DNA Measurements-A Clinically Applicable Surveillance Tool for Patients with HPV-Positive Oropharyngeal Cancer.
Jakobsen KK; Bendtsen SK; Pallisgaard N; Friborg J; Lelkaitis G; Grønhøj C; von Buchwald C
Clin Cancer Res; 2023 Oct; 29(19):3914-3923. PubMed ID: 37477909
[TBL] [Abstract][Full Text] [Related]
15. Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer.
Ahn SM; Chan JY; Zhang Z; Wang H; Khan Z; Bishop JA; Westra W; Koch WM; Califano JA
JAMA Otolaryngol Head Neck Surg; 2014 Sep; 140(9):846-54. PubMed ID: 25078109
[TBL] [Abstract][Full Text] [Related]
16. Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma.
Bhambhani C; Sandford E; Haring CT; Brummel C; Tuck KL; Olesnavich M; Bhangale AD; Walline HM; Dermody SM; Spector ME; Chinn SB; Casper K; Mierzwa M; Swiecicki PL; Chad Brenner J; Tewari M
Oral Oncol; 2023 Aug; 143():106436. PubMed ID: 37269557
[TBL] [Abstract][Full Text] [Related]
17. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
18. HPV circulating tumoral DNA quantification by droplet-based digital PCR: A promising predictive and prognostic biomarker for HPV-associated oropharyngeal cancers.
Veyer D; Wack M; Mandavit M; Garrigou S; Hans S; Bonfils P; Tartour E; Bélec L; Wang-Renault SF; Laurent-Puig P; Mirghani H; Rance B; Taly V; Badoual C; Péré H
Int J Cancer; 2020 Aug; 147(4):1222-1227. PubMed ID: 31756275
[TBL] [Abstract][Full Text] [Related]
19. Circulating HPV DNA as a Biomarker for Pre-Invasive and Early Invasive Cervical Cancer: A Feasibility Study.
Bryan SJ; Lee J; Gunu R; Jones A; Olaitan A; Rosenthal AN; Cutts RJ; Garcia-Murillas I; Turner N; Lalondrelle S; Bhide SA
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174056
[TBL] [Abstract][Full Text] [Related]
20. Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse.
Mittelstadt S; Kelemen O; Admard J; Gschwind A; Koch A; Wörz S; Oberlechner E; Engler T; Bonzheim I; Staebler A; Weidner N; Stubenrauch F; Iftner T; Riess O; Schroeder C; Kommoss S; Ossowski S
Br J Cancer; 2023 Jun; 128(11):2097-2103. PubMed ID: 36973448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
